

# Pioneering Developments in the Field of RNA: Interview Released with Advanced Cell Diagnostics

*Advanced Cell Diagnostics (ADC) to sponsor SMI's 7th annual RNA Therapeutics conference when it returns to London next month*

LONDON, ENGLAND, UNITED KINGDOM, January 26, 2016 /EINPresswire.com/ -- [RNA Therapeutics 2016](#) will discuss key topics in enabling RNA Therapeutics, whilst looking at the practicalities of targeting delivery, keeping attendees at the forefront of innovative developments and collaborative opportunities.

Event sponsors, Advanced Cell Diagnostics, is a leader in the emerging field of molecular pathology, developing cell and tissue based diagnostic tests for personalised medicine. In the run up to the show, SMI spoke to Europe's Senior Director for Sales and Marketing, Dr Kai Wilkens, about pioneering developments in the field of RNA and his

upcoming keynote presentation entitled: Single Copy Detection of Specific Transcripts in the Tissue.

Focusing on tissue specific assessment of efficacy and validation of RNAi approaches, Dr Wilkens will discuss key areas such as rapid biomarker development and validation; drug safety aspects and off-target effects in tissue samples; plus provide an A-Z guide in transferring from cell culture to animal models to clinical.



What is most amazing is the huge number of disease applications we see being worked on!

*Dr Kai Wilkens - ACD*

When asked about development in the field of RNA therapeutics he said:

“There have been many innovations and improvements in the field of drug delivery. In addition, chemical modifications of the RNA therapeutics in RNAi and synthetic mRNA therapy,

addressed various aspects of stability, immunogenicity and delivery of the drugs. What is most amazing is the huge number of disease applications we see being worked on!”

On RNAscope®, ACD's in situ hybridization assay, he commented:

“It now is possible to assess RNA therapeutics directly and in situ - with a simple and robust assay suitable for FFPE tissue samples as well as fresh-frozen ones. For mRNA therapeutics, the RNA drugs can be measured directly in cells and tissues. Within each tissue, the amount of mRNAs delivered to individual cells and cell types can be monitored and also checked for homogeneity. In RNAi approaches, the silencing effect on the target and/or other associated biomarkers can be looked



at in the same specific and sensitive manner. This works smoothly across all pre-clinical animal models and beyond. In this sense RNAscope can facilitate the optimization of delivery methods, which is an on-going challenge in the field.”

The full interview and a preliminary list of attendees is available in the conference [download centre](#).

For those who are interested in attending, there is currently a £500 saving available online at [www.rna-therapeutics.com](http://www.rna-therapeutics.com)

RNA Therapeutics  
15th and 16th February 2016  
Holiday Inn Kensington Forum, London UK

---END---

About SMi:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Teri Arri  
SMi Group  
+442078276000  
[email us here](#)

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.